Timothy Stonesifer Acquires 2,790 Shares of Insulet (NASDAQ:PODD) Stock

Insulet Corporation (NASDAQ:PODD) Director Timothy Stonesifer bought 2,790 shares of the firm’s stock in a transaction that occurred on Wednesday, June 3rd. The stock was purchased at an average cost of $143.51 per share, for a total transaction of $400,392.90. Following the completion of the purchase, the director owned 9,041 shares of the company’s stock, valued at $1,297,473.91. This trade represents a 44.63% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Insulet Stock Up 4.7%

Shares of NASDAQ PODD opened at $153.22 on Friday. The company has a quick ratio of 1.81, a current ratio of 2.49 and a debt-to-equity ratio of 0.71. Insulet Corporation has a 52 week low of $140.63 and a 52 week high of $354.88. The firm’s fifty day moving average is $175.73 and its 200 day moving average is $238.90. The company has a market cap of $10.61 billion, a price-to-earnings ratio of 35.63, a PEG ratio of 1.15 and a beta of 1.13.

Insulet (NASDAQ:PODD) last issued its earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 EPS for the quarter, topping the consensus estimate of $1.19 by $0.23. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The company had revenue of $761.70 million for the quarter, compared to the consensus estimate of $729.89 million. During the same period in the previous year, the firm earned $1.02 earnings per share. The firm’s revenue for the quarter was up 33.9% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.210- EPS. On average, equities research analysts expect that Insulet Corporation will post 6.46 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts recently commented on the stock. Wells Fargo & Company decreased their target price on shares of Insulet from $360.00 to $255.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 6th. JPMorgan Chase & Co. decreased their target price on shares of Insulet from $340.00 to $275.00 and set an “overweight” rating on the stock in a research note on Thursday, May 7th. Raymond James Financial reduced their price objective on shares of Insulet from $355.00 to $263.00 in a research report on Thursday, May 7th. Evercore reduced their price objective on shares of Insulet from $240.00 to $200.00 in a research report on Thursday, May 7th. Finally, Leerink Partners reduced their price objective on shares of Insulet from $360.00 to $247.00 in a research report on Thursday, May 7th. Twenty-one analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Insulet currently has a consensus rating of “Moderate Buy” and an average target price of $252.04.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in PODD. NewEdge Advisors LLC increased its position in Insulet by 44.8% during the 1st quarter. NewEdge Advisors LLC now owns 207 shares of the medical instruments supplier’s stock valued at $54,000 after purchasing an additional 64 shares during the period. Cresset Asset Management LLC increased its position in Insulet by 7.3% during the 2nd quarter. Cresset Asset Management LLC now owns 2,587 shares of the medical instruments supplier’s stock valued at $813,000 after purchasing an additional 177 shares during the period. Cerity Partners LLC increased its position in Insulet by 68.7% during the 2nd quarter. Cerity Partners LLC now owns 17,262 shares of the medical instruments supplier’s stock valued at $5,423,000 after purchasing an additional 7,030 shares during the period. Sei Investments Co. grew its position in shares of Insulet by 27.4% in the 2nd quarter. Sei Investments Co. now owns 137,643 shares of the medical instruments supplier’s stock worth $43,245,000 after buying an additional 29,584 shares during the period. Finally, Treasurer of the State of North Carolina grew its position in shares of Insulet by 2.5% in the 2nd quarter. Treasurer of the State of North Carolina now owns 32,752 shares of the medical instruments supplier’s stock worth $10,290,000 after buying an additional 791 shares during the period.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.